OTCMKTS:NVZMY - Novozymes A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$73.99
▼ -0.28 (-0.38%)
1 month | 3 months | 12 months
Get New Novozymes A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVZMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVZMY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Novozymes A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $73.99.

Hold

The current consensus among 7 contributing investment analysts is to hold stock in Novozymes A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 3 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 3 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 3 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/10/2021BarclaysReiterated RatingOverweight
i
5/4/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
4/30/2021Berenberg BankReiterated RatingHold
i
4/28/2021UBS GroupReiterated RatingSell
i
4/28/2021Credit Suisse GroupReiterated RatingUnderperform
i
4/28/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
i
2/9/2021BarclaysReiterated RatingOverweight
i
2/3/2021Berenberg BankUpgradeSell ➝ Hold
i
1/26/2021DanskeUpgradeSell ➝ Hold
i
1/25/2021BarclaysUpgradeUnderweight ➝ Overweight
i
11/18/2020BarclaysReiterated RatingUnderweight
i
10/8/2020Berenberg BankDowngradeHold ➝ Sell
i
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
8/13/2020BarclaysReiterated RatingUnderweight
i
7/28/2020BarclaysInitiated CoverageUnderweight
i
7/8/2020UBS GroupReiterated RatingSell
i
7/2/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
5/12/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform
i
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell
i
1/14/2020BNP ParibasDowngradeOutperform ➝ Neutral
i
1/7/2020The Goldman Sachs GroupInitiated CoverageBuy
i
12/17/2019Berenberg BankDowngradeBuy ➝ Hold
i
11/20/2019CitigroupUpgradeNeutral ➝ Buy
i
9/30/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
8/19/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
3/26/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
2/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy
i
2/5/2019Berenberg BankUpgradeHold ➝ Buy
i
1/30/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
1/28/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
i
12/20/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
10/30/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
3/5/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
10/26/2017Jefferies Financial GroupReiterated RatingHold$54.97
i
Rating by Akshay Jagdale at Jefferies Financial Group Inc.
8/14/2017Jefferies Financial GroupSet Price TargetHold$48.00
i
Rating by Akshay Jagdale at Jefferies Financial Group Inc.
5/10/2017Jefferies Financial GroupReiterated RatingHold$47.50
i
5/9/2017Jefferies Financial GroupReiterated RatingHold$47.50
i
2/10/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
2/1/2017The Goldman Sachs GroupDowngradeNeutral ➝ Sell
i
1/5/2017Sanford C. BernsteinUpgradeMkt Perform ➝ Outperform
i
12/9/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
11/1/2016Berenberg BankUpgradeSell ➝ Hold
i
10/7/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold
i
9/27/2016Berenberg BankInitiated CoverageSell
i
(Data available from 6/14/2016 forward)
Novozymes A/S logo
Novozymes A/S produces and sells industrial enzymes and microorganisms in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, cellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, and professional cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim abrasion and finishing, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has collaboration with FMC Corporation to co-develop enzyme solutions. The company is based in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $73.99
$72.64
$74.47

50 Day Range

MA: $70.78
$62.84
$75.41

52 Week Range

Now: $73.99
$54.55
$75.72

Volume

8,900 shs

Average Volume

12,754 shs

Market Capitalization

$16.89 billion

P/E Ratio

45.67

Dividend Yield

0.76%

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Novozymes A/S?

The following Wall Street research analysts have issued research reports on Novozymes A/S in the last year: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Danske, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for NVZMY.

What is the current price target for Novozymes A/S?

0 Wall Street analysts have set twelve-month price targets for Novozymes A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Novozymes A/S in the next year.
View the latest price targets for NVZMY.

What is the current consensus analyst rating for Novozymes A/S?

Novozymes A/S currently has 2 sell ratings, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVZMY, but not buy more shares or sell existing shares.
View the latest ratings for NVZMY.

What other companies compete with Novozymes A/S?

How do I contact Novozymes A/S's investor relations team?

Novozymes A/S's physical mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company's listed phone number is 45-4446-0000 and its investor relations email address is [email protected] The official website for Novozymes A/S is www.novozymes.com.